Skip to main content
Clinical Trials/IRCT138904263325N3
IRCT138904263325N3Completed未知

Effect of short-term and low amount of intravenous Ascorbic Acid on reducing ferritin in Hemodialysis Patients without increasing the start dosage of erythropoietin: crossed over double blind randomized controlled trial

Zanjan University of Medical Sciences0 sites30 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Enrollment
30

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
no limit to no limit (—)
Sex
All

Inclusion Criteria

  • receiving hemodialysis therapy for at least 6 months, administered EPO for 6 months or longer at a dose of 80-360 U/kg/wk or greater, rolling 3-month average Hb level of 11.0 g/dL or less (110 g/L), ferritin level greater than 500 ng/Ml, transferrin saturation (TSAT) of 20% or less and administered maintenance intravenous iron (25-100 mg/week)
  • Exclusion criteria: bone marrow malignancy, myelodysplastic syndrome, evidence of chronic infection, hemochromatosis, hemoglobinopathies, evidence of significant bleeding (decrease in Hb level = 2 g/dL during the past 3 months, mean corpuscular volume greater than 100 fL, biointact parathyroid hormone (bio-PTH) level greater than 500 pg/mL (ng/L)

Exclusion Criteria

  • Not provided

Investigators

Similar Trials